Curis Corp - נכסים נקיים למניה בודדת CRIS
The historical book value dynamics of Curis, Inc. (CRIS) shares on the GURU.Markets interface show a lack of approved drugs and a budget dependent on equity offerings, while the 2.41 level records fresh values. The business relies on intellectual property licensing to generate royalties. Additionally, Curis, Inc. (CRIS) develops high-precision molecules that block tumor division to achieve the complete elimination of severe forms of cancer.
פילוחי נתונים אנליטיים מרוכזים עבור Curis Inc. (CRIS)
Book value per share reflects the net capital value attributable to a single security, allowing investors to assess the company's actual internal reserves net of liabilities. The trend in expected book value per share demonstrates the pace of asset accumulation for Curis, Inc. (CRIS) amid fierce competition for oncology patents and the risks posed by the emergence of more affordable immunotherapy methods.